Literature DB >> 10490952

Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells.

G Ferlazzo1, A Wesa, W Z Wei, A Galy.   

Abstract

Dendritic cells (DC) can be generated in vitro from monocytes (M-DC) or from CD34+ hemopoietic progenitor cells (CD34-DC) but their precursors are not equivalent cells, prompting a comparison of the functional capacities of these APC. Both types of DCs established from the same individuals using the same cytokines displayed a comparable phenotype of mature DC (CD1a+, CD83+, CD86+, CD4+, HLA-DR++, CD14-, CD15- ) and were equally potent stimulators of allogeneic T cell proliferation, being both more powerful than immature M-DCs. An autologous panel of APCs produced in HLA-A2+ individuals, including CD34-DC, M-DC, monocytes, and EBV-lymphoid cell line was comparatively evaluated for presentation of the Erb-B2 peptide E75 to a CTL line. After short exposures (5 h) to E75-loaded APCs, similar levels of intracellular IFN-gamma were induced in Ag-specific CD8+ T cells regardless of APC type. In sustained cultures (4-14 days), more Ag-specific T cells were obtained when peptide was presented on CD34-DC (p < 0.05) rather than on M-DC, EBV-lymphoid cell lines, or monocytes, and these effects were dose-dependent. Activated T cells expressed 4-1BB, and the presence of 4-1BB-Ig fusion protein partially blocked Ag-specific CD8+ cell activation after CD34-DC or M-DC presentation. Our results show that 34-DC have a preferential capacity to activate CD8+ T cells and that this property is not strictly correlated to their ability to induce allogeneic T cell proliferation but due to mechanisms that remain to be defined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490952

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells.

Authors:  P A MacAry; M Lindsay; M A Scott; J I Craig; J P Luzio; P J Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.

Authors:  Hideki Fujita; Mayte Suárez-Fariñas; Hiroshi Mitsui; Juana Gonzalez; Mark J Bluth; Shali Zhang; Diane Felsen; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

Review 4.  Dendritic cells derived from pluripotent stem cells: Potential of large scale production.

Authors:  Yan Li; Meimei Liu; Shang-Tian Yang
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

5.  Isolation of dendritic cells from umbilical cord blood using magnetic activated cell sorting or adherence.

Authors:  Yachun Bie; Qiuxiang Xu; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

6.  The plasticity and potential of leukemia cell lines to differentiate into dendritic cells.

Authors:  Qingwei Guo; Leling Zhang; Fu Li; Guosheng Jiang
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

7.  In vitro generation of human CD86+ dendritic cells from CD34+ haematopoietic progenitors by PMA and in serum-free medium.

Authors:  G Ramadan; R E Schmidt; J Schubert
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

8.  A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes.

Authors:  Mariana Mesel-Lemoine; Jean Millet; Pierre-Olivier Vidalain; Helen Law; Astrid Vabret; Valérie Lorin; Nicolas Escriou; Matthew L Albert; Béatrice Nal; Frédéric Tangy
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

Review 9.  Immune modulation by dendritic-cell-based cancer vaccines.

Authors:  Chaitanya Kumar; Sakshi Kohli; Poonamalle Parthasarathy Bapsy; Ashok Kumar Vaid; Minish Jain; Venkata Sathya Suresh Attili; Bandana Sharan
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

10.  Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.

Authors:  Naoya Ukyo; Toshiyuki Hori; Soshi Yanagita; Takayuki Ishikawa; Takashi Uchiyama
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.